白 瑞,周 玲

本文探讨新冠疫情后儿童肺炎支原体肺炎（MPP）的现状及影响。疫情初期非药物性干预措施抑制了肺炎支原体（MP）传播，后随着措施放宽，2023年秋冬季MPP病例显著反弹，儿童中呈现感染低龄化、症状加重、混合感染增多趋势。文章分析了MPP流行病学特征、临床表现、诊断及治疗策略，指出大环内酯类药物耐药性带来挑战，还讨论了MP生物学特性、感染机制及与新冠病毒相互作用，强调后疫情时代防控需个体化治疗、长期监测和综合预防。本文为防控提供新视角与策略，呼吁关注MPP新变化，提高诊疗效果，保障儿童健康权益。

儿童；肺炎支原体肺炎；新冠疫情

[1] Peluso,M.J.;Deitchman,A.N.;Torres,L.;Iyer,N.S.;Munter,S.E.;Nixon,C.C.;Donatelli,J.;Thanh,C.;Takahashi,S.;Hakim,J.;et al.Long-Term SARS-CoV-2-Specific Immune and Inflammatory Responses in Individuals Recovering from COVID-19 with and without Post-Acute Symptoms.Cell Rep.2021,36,109518. [2] Ryan,F.J.;Hope,C.M.;Masavuli,M.G.;Lynn,M.A.;Mekonnen,Z.A.;Yeow,A.E.L.;Garcia-Valtanen,P.;Al-Delfi,Z.;Gummow,J.;Ferguson,C; et al.Long-Term Perturbation of the Peripheral Immune System Months after SARS-CoV-2 Infection.BMC Med.2022,20,26. [3] Zhang,X.-B.;He,W.;Gui,Y.-H.;Lu,Q.;Yin,Y.;Zhang,J.-H.;Dong,X.-Y.;Wang,Y.-W.;Ye,Y.-Z.;Xu,H.;et al.Current Mycoplasma pneumoniae Epidemic among Children in Shanghai:Unusual Pneumonia Caused by Usual Pathogen.World J.Pediatr.2024,20,5–10. [4] Yang,S.;Lu,S.;Guo,Y.;Luan,W.;Liu,J.;Wang,L.A Comparative Study of General and Severe Mycoplasma pneumoniae Pneumonia in Children.BMC Infect.Dis.2024,24,449. [5] Li X,Li T,Chen N,Kang P,Yang J.Changes of Mycoplasma pneumoniae prevalence in children before and after COVID-19 pandemic in Henan,China.J Infect 2023;86:256–308. [6] Yan,C.;Xue,G.-H.;Zhao,H.-Q.;Feng,Y.-L.;Cui,J.-H.;Yuan,J.Current Status of Mycoplasma pneumoniae Infection in China.World J. Pediatr.2024,20,1–4. [7] Edouard,S.;Boughammoura,H.;Colson,P.;La Scola,B.;Fournier,P.-E.;Fenollar,F.Large-Scale Outbreak of Mycoplasma pneumoniae Infection,Marseille,France,2023–2024.Emerg.Infect.Dis.2024,30,1481–1484. [8] Xiao L,Ptacek T,Osborne JD,Crabb DM,Simmons WL,et al.Comparative genome analysis of Mycoplasma pneumoniae.BMC Genom 2015;16:610. [9] Dumke R.Molecular tools for typing Mycoplasma pneumoniae and Mycoplasma genitalium.Front Microbiol 2022;13. [10] Kenri T,Yamazaki T,Ohya H,Jinnai M,Oda Y,et al.Genotyping of Mycoplasma pneumoniae strains isolated in Japan during 2019 and 2020:spread of p1 gene type 2c and 2j variant strains.Front Microbiol 2023;14:1202357. [11] Dumke R,Catrein I,Herrmann R,Jacobs E.Preference,adaptation and survival of Mycoplasma pneumoniae subtypes in an animal model.Int J Med Microbiol 2004;294:149–155. [12] Meyer Sauteur,P.M.;Seiler,M.;Trück,J.;Unger,W.W.J.;Paioni,P.;Relly,C.;Staubli,G.;Haas,T.;Gysin,C.;Bachmann,L.M.;et al.Diagnosis of Mycoplasma pneumoniae Pneumonia with Measurement of Specific Antibody-Secreting Cells.Am.J.Respir.Crit.Care Med.2019, 200, 1066–1069. [13] Meyer Sauteur,P.M.;Trück,J.;van Rossum,A.M.C.;Berger,C.Circulating Antibody-Secreting Cell Response during Mycoplasma pneumoniae Childhood Pneumonia.J.Infect.Dis.2020,222,136–147. [14] Lai,W.-C.;Hsieh,Y.-C.;Chen,Y.-C.;Kuo,C.-Y.;Chen,C.-J.;Huang,Y.-C.;Chiu,C.-H.;Lin,T.-Y.;Huang,K.-Y.A.A Potent Antibody-Secret-ing B Cell Response to Mycoplasma pneumoniae in Children with Pneumonia.J.Microbiol.Immunol.Infect.2022,55,413–420. [15] Iseki,M.;Takahashi,T.;Kimura,K.;Yamashita,R.;Sasaki,T.Number of Specific Antibody-Secreting Cells in the Peripheral Blood among Children with Mycoplasma pneumonia.Infect.Immun.1996,64,2799–2803. [16] Carter,M.J.;Mitchell,R.M.;Meyer Sauteur,P.M.;Kelly,D.F.;Trück,J.The Antibody-Secreting Cell Response to Infection:Kinetics and Clinical Applications.Front.Immunol.2017,8,630. [17] Saletti,G.;Çuburu,N.;Yang,J.S.;Dey,A.;Czerkinsky,C.Enzyme-Linked Immunospot Assays for Direct Ex Vivo Measurement of Vaccine-Induced Human Humoral Immune Responses in Blood.Nat.Protoc.2013,8,1073–1087. [18] Tsai TA,Tsai CK,Kuo KC,et al.Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children.J Microbiol Immunol Infect.2021;54(4):557–565. [19] Dai FF,Liu FQ,Chen X,et al.The treatment of macrolide-resistant Mycoplasma pneumoniaepneumonia in children.J Clin Pharm Ther. 2021;46(3):705–710. [20] He YS,Yang M,Liu G,et al.Safety study of moxifloxacin in children with severe refractory Mycoplasma pneumoniae pneumonia. Pediatr Pulmonol.2023;58(7):2017–2024. [21] Cao B,Zhao CJ,Yin YD,et al.High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China.Clin Infect Dis.2010;51(2):189–194. [22] Yin YD,Cao B,Wang H,et al.Survey of macrolide resistance in Mycoplasma pneumoniae in adult patients with community-acquired pneumonia in Beijing,China.Zhonghua Jie He Hu Xi Za Zhi.2013;36(12):954–958. [23] Kawai Y,Miyashita N,Kubo M,et al.Therapeutic efficacy of macrolides,minocycline,and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients.Antimicrob Agents Chemother.2013;57(5):2252–2258. [24] Cao B,Qu JX,Yin YD,et al.Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia:focus on macrolide resistance. Clin Respir J.2017;11(4):419–429. [25] Owens RC,Jr.,Ambrose PG.Antimicrobial safety:focus on fluoroquinolones.Clin Infect Dis.2005;41 Suppl 2:S144–S157. [26] Chen L,Liu J,Zhao S,et al.Clinical features and treatment of refractory Mycoplasma pneumoniae pneumonia unresponded to conventional dose methylprednisolone in children.Zhonghua Er Ke Za Zhi.2014;52(3):172–176. [27] Liu J,He R,Zhang X,et al.Clinical features and“early”corticosteroid treatment outcome of pediatric Mycoplasma pneumoniae pneumonia.Front Cell Infect Microbiol.2023;13:1135228. [28] Lee YC,Chang CH,Lee WJ,et al.Altered chemokine profile in refractory Mycoplasma pneumoniae pneumonia infected children.J Microbiol Immunol Infect.2021;54(4):673–679. [29] Luo Z,Luo J,Liu E,et al.Effects of prednisolone on refractory Mycoplasma pneumoniae pneumonia in children.Pediatr Pulmonol. 2014;49(4):377–380. [30] Lan Y,Yang D,Chen Z,et al.Effectiveness of methylprednisolone in treatment of children with refractory Mycoplasma pneumoniae pneumonia and its relationship with bronchoalveolar lavage cytokine levels.Zhonghua Er Ke Za Zhi.2015;53(10):779–783. [31] Zhu Z,Zhang T,Guo W,et al.Clinical characteristics of refractory Mycoplasma pneumoniae pneumonia in children treated with glucocorticoid pulse therapy.BMC Infect Dis.2021;21(1):126. [32] Chambert-Loir C,Ouachee M,Collins K,et al.Immediate relief of Mycoplasma pneumoniae encephalitis symptoms after intravenous immunoglobulin.Pediatr Neurol.2009;41(5):375–377. [33] Wang Y,Liu K,Chen C,et al.Acetylcysteine and budesonide for the treatment of refractory Mycoplasma pneumoniae pneumonia in children:a clinical observation.Ital J Pediatr.2023;49(1):80. [34] Smith CB,Chanock RM,Friedewald WT,Alford RH.Mycoplasma pneumoniae infections in volunteers.Ann N Y Acad Sci 1967; 143:471–483. [35] Gavitt TD,Mara AB,Goodridge ML,Ozyck RG,Reinhardt E,et al.B cells oppose Mycoplasma pneumoniae vaccine enhanced disease and limit bacterial colonization of the lungs.NPJ Vaccines 2022;7:130. [36] Mara AB,Gavitt TD,Tulman ER,Geary SJ,Szczepanek SM.Lipid moieties of Mycoplasma pneumoniae lipoproteins are the causative factor of vaccine-enhanced disease.NPJ Vaccines 2020;5:31.

点击下载PDF